In subgroup analyses, we analyzed whether predictive performance and detected features differed between subsets of patients. Due to the small sample size, these exploratory subgroup analyses were performed on the combined training and test data sets. We investigated the performance in presymptomatic PLN p.Arg14del mutation carriers. Presymptomatic was defined as follows: no cardiac symptoms as per judgment of the treating physician, no history of (non)sustained ventricular arrhythmia, premature ventricular complex burden of <500 beats per 24 hours and left ventricular ejection fraction ≥45%.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.